Ceftolozane-tazobactam (C/T), the combination of a new cephalosporin with a classic β-lactamase inhibitor, is currently considered the most active betalactam antibiotic against *P. aeruginosa* \[[@CR1]\]. Despite several case reports on C/T pharmacokinetics in critically ill patients during continuous renal replacement therapy (CRRT) \[[@CR2]--[@CR4]\], the optimal dose in this clinical scenario still remains unclear \[[@CR5]\].

A 68-year-old patient was admitted to our ICU with septic shock (nosocomial peritonitis) and anuric acute renal failure. Broad-spectrum antimicrobial therapy, including C/T and continuous venovenous hemodiafiltration (CVVHD), was initiated, using a polysulphone hemofilter (Fresenius, Germany) with blood flow, dialysate fluid, and replacement fluid rates of 100 mL/min, 2000 mL/h, and 1000 mL/h. The patient received high C/T doses of C/T 2 g/1 g every 8 h (infused over 1 h) while receiving CVVHD, and became apyrexial 7 days after C/T treatment initiation, remaining fever-free for 14 days without any adverse effects related to this drug.

Pre-filter and post-filter blood and ultradiafiltrate samples were obtained during the 8-h dosing interval after the fourth dose. Drug concentrations were measured by high-performance liquid chromatography. Figure [1](#Fig1){ref-type="fig"} and Table [1](#Tab1){ref-type="table"} show pre- and post-filter plasma concentrations. Pharmacokinetic parameters were calculated (Table [2](#Tab2){ref-type="table"}). Extraction ratios were high for both ceftolozane and tazobactam (49.3% ± 1.8% and 40.5% ± 4.5%). Mean C/T concentrations in the ultrafiltrate were 40 mg/L and 13.5 mg/L, respectively.Fig. 1Simulated plasma concentrations versus time curves for ceftolozane and tazobactam. Pre-filter (thick line) and post-filter (fine line) ceftolozane plasma concentrations and pre-filter (thick dotted line) and post-filter (fine dotted line) tazobactam plasma concentrations. (The figure is original for this article)Table 1Concentrations of ceftolozane and tazobactam in pre-filter and post-filter plasma samples obtained after the fourth dose of 2 g/1 g ceftolozane-tazobactam administered as intravenous 1-h infusionSampling timeCeftolozane (mg/L)Tazobactam (mg/L)Pre-filterPost-filterPre-filterPost-filter0 h (pre dose)41.920.710.65.81.5 h post dose89.145.228.312.22 h post dose80.338.421.610.32.5 h post dose77.136.119.09.03 h post dose73.834.716.38.25 h post dose66.630.614.27.47 h post dose60.228.712.76.08 h post dose55.825.811.45.1Table 2Pharmacokinetic parameters of ceftolozane and tazobactamParameterCeftolozaneTazobactamPre-filterPost-filterPre-filterPost-filterClearance (L/h)2.15.46.417.4Volume of distribution (L)53.997.5108.9194.2Half-life (h)17.912.611.97.8AUC (h mg/L)96037315757.6Maximum concentration (mg/L)99533714.5Minimum concentration (mg/L)55.925.811.45.1*AUC* area under the concentration-time curve

We decided on a 3 g/iv dose every 8 h, taking into account two previous studies \[[@CR3], [@CR4]\] and a recent study which showed CRRT to be an independent predictor of clinical failure (OR 4.5, 95% CI 1.18--17.39, *p* = 0.02) when C/T is administered at 1.5 g every 8 h \[[@CR5]\].

Ceftolozane and tazobactam are small molecules with low plasma protein binding rates, causing most to be removed during CRRT. Despite the considerable C/T clearance observed in our patients during CVVHD, however, ceftolozane plasma concentrations remained above the MIC, for MICs of up to 8 μg/mL, throughout the dosing interval, assuming 20% protein binding. Given that C/T exhibits linear, dose-proportional pharmacokinetics, a standard C/T dose of 1 g/0.5 g would be expected to maintain ceftolozane levels above the MIC during the entire dosing interval, although tazobactam concentrations could be insufficient, even taking higher pre-filter rather than lower post-filter levels as representative of therapeutic serum levels.

In conclusion, our data underscore that a dosage of 3 g every 8 h can be used safely to prevent the potential harm of underdosing ceftolozane/tazobactam during CRRT; larger studies are however needed to confirm our findings.
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